CARsgen Presents Preliminary Results on Satri-cel for Adjuvant Therapy of Pancreatic Cancer at ESMO Congress 2025

Core Insights - CARsgen Therapeutics has presented promising results from a Phase Ib clinical trial of satricabtagene autoleucel ("satri-cel") for pancreatic cancer at the ESMO Congress 2025, marking a significant advancement in CAR T-cell therapy for solid tumors [1][4][6] Clinical Trial Details - The trial involved patients with Claudin18.2 positive pancreatic ductal adenocarcinoma (PDAC) who had undergone curative-intent resection and showed elevated CA19-9 levels post-chemotherapy [2][3] - Six patients were infused with satri-cel, with a median follow-up of 6.05 months, where only one patient experienced disease recurrence, indicating a promising disease-free survival rate [4][5] Efficacy and Safety - The 9-month disease-free survival (DFS) rate was reported at 83.3%, with significant declines in CA19-9 levels observed in 83.3% of patients, ranging from 51.3% to 96.1% [4][6] - Adverse effects included Grade 1 or 2 cytokine release syndrome (CRS) in all patients, with one case of Grade 3 CRS, which was manageable [5] Future Directions - The company is advancing clinical trials for satri-cel in gastric cancer adjuvant therapy and aims to provide better treatment options for a broader patient population [6][8] - Satri-cel has received various designations from regulatory bodies, including Breakthrough Therapy Designation and Priority Review from the CDE in China, indicating its potential as a first-in-class therapy [7]